

Applicant:

I hereby certify that this correspond being deposited with the United States

Postal Service as first class mail an envelope addressed to: Commissioner for Patents, Office of Tatial Patent Examination, Customer

Center, Washington, D.C. 20231 on:

of Person/ Making

Date of Signature

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No .: 09/848,159 Filed: May 3, 2001 For: METHODS OF TREATING HYPERLIPIDEMIA Group Art Unit: 1617 Not Yet Assigned Examiner:

Klein et al.

#### NOTICE OF CORRECTION OF FILING RECEIPT

**Assistant Commissioner for Patents** Office of Initial Patent Examination **Customer Correction Branch** Washington, D.C. 20231

Dear Sir:

Please correct the filing receipt as follows:

#### **Assignment For Published Patent Application**

Delete "Allergan Inc.," and insert in place thereof -- Allergan Sales, Inc.-- (Enclosed is a copy of the recorded assignment.)

No fee is thought to be required, but if applicant is in error in this regard, please use

Deposit Account 01-0885 for payment of any fee that may be due.

Dated:

By:

Respectfully submitted,

Registration No. 36,510 Attorney of Record

ALLERGAN, INC.

Legal Department 2525 Dupont Drive

Irvine, CA. 92612

Telephone: (714) 246-4920 Facsimile: (714) 246-4249

# INTED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PA

UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON. D.C. 20231

www.USBIO.DOV

Page 1 of

APPLICATION NUMBER 09/848,159

FILING DATE 05/03/2001 GRP ART UNIT 1614

FIL FEE REC'D ATTY DOCKET NO DRAWINGS 818

D2977

IND CLAIMS TOT CLAIMS 26

**CONFIRMATION NO. 7424** 

FILING RECEIPT

Frank J Uxa Stout, Uxa, Buyan & Mullins, LLP Suite 300

4 Venture Irvine, CA 92618 7416

00000000005268835

Date Mailed. 07/09/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filling Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filling Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)

Yang-Dar Yuan, Irvine, CA; Scott M. Thacher, Costa Mesa, CA; Elliott S Klein, Danbury, CT. Roshantha A Chandraratna, Laguna Hills, CA;

### **Assignment For Published Patent Application**

-Allergan Inc., Irvine, CA; ALLERGAN SALES, INC. Domestic Priority data as claimed by applicant

Foreign Applications

If Required, Foreign Filing License Granted 07/05/2001

Projected Publication Date: 11/07/2002

Non-Publication Request: No

Early Publication Request: No

JUL 1 3 2001

Title

Methods of treating hyperlipidemia

**Preliminary Class** 

514

. Data entry by : GEBRESILASSIE, FREWOINI

Team : OIPE

Date: 07/09/2001

- 1 CODE CON LAND CON LAND CON CONTROL CON CONTROL CON CONTROL CONTROL CONTROL CONTROL CONTROL CONTROL CONTROL

# LICENSE FOR FOREIGN FILING UNDER Title 35. United States C de, Secti n 184 Title 37. C de f Federal Regulati ns, 5.11 & 5.15

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1 53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### NOT GRANTED

No license under 35 U.S.C 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

## PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a." "an" and "the" are not included as the first words in the title of an application.
   They are considered to be unnecessary to the understanding of the title
   The words "new." "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
   The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231